JP6993348B2 - β－アミノパテアミンＡ誘導体及び慢性リンパ球性白血病を治療する方法 - Google Patents
β－アミノパテアミンＡ誘導体及び慢性リンパ球性白血病を治療する方法 Download PDFInfo
- Publication number
- JP6993348B2 JP6993348B2 JP2018551799A JP2018551799A JP6993348B2 JP 6993348 B2 JP6993348 B2 JP 6993348B2 JP 2018551799 A JP2018551799 A JP 2018551799A JP 2018551799 A JP2018551799 A JP 2018551799A JP 6993348 B2 JP6993348 B2 JP 6993348B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound according
- racemate
- acceptable salt
- equation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@@](C[C@](CC(O[C@@](C)CC(C)=CC=CC(O[C@@](*1)C=C(C)C=CC(C)=CCN(C)C)=O)=O)N)c2c[s]c1n2 Chemical compound C[C@@](C[C@](CC(O[C@@](C)CC(C)=CC=CC(O[C@@](*1)C=C(C)C=CC(C)=CCN(C)C)=O)=O)N)c2c[s]c1n2 0.000 description 17
- GMELMFSDPDSXOZ-UHFFFAOYSA-N CC(C)(C(Cl)(Cl)Cl)OC(Cl)=O Chemical compound CC(C)(C(Cl)(Cl)Cl)OC(Cl)=O GMELMFSDPDSXOZ-UHFFFAOYSA-N 0.000 description 1
- LTKHSJHINPMUTC-KEXYBWNXSA-N CC/N=C(/C[C@@H](/C=C(\C)/Br)O1)\SOCO[C@@H](C)C/C(/C)=C/C=C\C1=O Chemical compound CC/N=C(/C[C@@H](/C=C(\C)/Br)O1)\SOCO[C@@H](C)C/C(/C)=C/C=C\C1=O LTKHSJHINPMUTC-KEXYBWNXSA-N 0.000 description 1
- VSVORQIMRUVRPE-MMPYLIGOSA-N C[C@@H](C/C(/C)=C/C=C\C(O[C@@H](Cc1nc(CCCC2)c[s]1)/C=C(\C)/C=C/C(/C)=C/CN(C)C)=O)OC2=O Chemical compound C[C@@H](C/C(/C)=C/C=C\C(O[C@@H](Cc1nc(CCCC2)c[s]1)/C=C(\C)/C=C/C(/C)=C/CN(C)C)=O)OC2=O VSVORQIMRUVRPE-MMPYLIGOSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316299P | 2016-03-31 | 2016-03-31 | |
| US62/316,299 | 2016-03-31 | ||
| PCT/US2017/025448 WO2017173313A1 (en) | 2016-03-31 | 2017-03-31 | Beta-amimo pateamine a derivatives and methods for treating chronic lymphocytic leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510070A JP2019510070A (ja) | 2019-04-11 |
| JP2019510070A5 JP2019510070A5 (https=) | 2020-05-07 |
| JP6993348B2 true JP6993348B2 (ja) | 2022-02-15 |
Family
ID=59965302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551799A Active JP6993348B2 (ja) | 2016-03-31 | 2017-03-31 | β－アミノパテアミンＡ誘導体及び慢性リンパ球性白血病を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10889596B2 (https=) |
| EP (1) | EP3436007B1 (https=) |
| JP (1) | JP6993348B2 (https=) |
| CA (1) | CA3018192C (https=) |
| DK (1) | DK3436007T3 (https=) |
| ES (1) | ES2913210T3 (https=) |
| WO (1) | WO2017173313A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024254195A1 (en) * | 2023-06-06 | 2024-12-12 | Baylor University | Methods for treating pancreatic cancer with a combination of des-methyl pateamine a and a class 1 hdac inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005531514A (ja) | 2002-03-13 | 2005-10-20 | ザ テキサス エー アンド エム ユニバーシティー システム | 効力のある簡素化した免疫抑制剤誘導体 |
| WO2013152299A2 (en) | 2012-04-06 | 2013-10-10 | University Of North Carolina At Chapel Hill | Inhibitors of eif4a and derivatives of pateamine a with antiviral activity and use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0647645A1 (en) | 1993-10-12 | 1995-04-12 | Pharma Mar, S.A. | Novel antitumoral and antiviral compound |
| US7737134B2 (en) | 2002-03-13 | 2010-06-15 | The Texas A & M University System | Anticancer agents and use |
| US20130053994A1 (en) * | 2011-08-31 | 2013-02-28 | General Electric Company | Method and apparatus for monitoring radiopharmaceutical processing |
-
2017
- 2017-03-31 DK DK17776804.1T patent/DK3436007T3/da active
- 2017-03-31 ES ES17776804T patent/ES2913210T3/es active Active
- 2017-03-31 EP EP17776804.1A patent/EP3436007B1/en active Active
- 2017-03-31 US US16/090,528 patent/US10889596B2/en active Active
- 2017-03-31 WO PCT/US2017/025448 patent/WO2017173313A1/en not_active Ceased
- 2017-03-31 JP JP2018551799A patent/JP6993348B2/ja active Active
- 2017-03-31 CA CA3018192A patent/CA3018192C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005531514A (ja) | 2002-03-13 | 2005-10-20 | ザ テキサス エー アンド エム ユニバーシティー システム | 効力のある簡素化した免疫抑制剤誘導体 |
| WO2013152299A2 (en) | 2012-04-06 | 2013-10-10 | University Of North Carolina At Chapel Hill | Inhibitors of eif4a and derivatives of pateamine a with antiviral activity and use |
Non-Patent Citations (2)
| Title |
|---|
| Bioorganic & Medicinal Chemistry，2014年，Vol.22，pp.116-125 |
| PHARMACOLOGICAL REVIEWS，2015年，Vol.68, No.1，pp.3-19 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017173313A1 (en) | 2017-10-05 |
| EP3436007A1 (en) | 2019-02-06 |
| EP3436007A4 (en) | 2019-10-09 |
| EP3436007B1 (en) | 2022-03-02 |
| DK3436007T3 (da) | 2022-03-14 |
| US10889596B2 (en) | 2021-01-12 |
| JP2019510070A (ja) | 2019-04-11 |
| CA3018192A1 (en) | 2017-10-05 |
| US20190177339A1 (en) | 2019-06-13 |
| CA3018192C (en) | 2025-05-06 |
| ES2913210T3 (es) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240270736A1 (en) | Macrocyclic heterocycles and uses thereof | |
| AU2021269433A1 (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
| CN102906090B (zh) | 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用 | |
| WO2019201123A1 (zh) | 一种多功能化合物、其制备方法及其在医药上的应用 | |
| AU2022389555A1 (en) | Antibody-drug conjugate and use thereof | |
| JP2020525513A (ja) | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 | |
| JP2022521605A (ja) | 統合的ストレス応答経路の阻害剤 | |
| EP4527415A1 (en) | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof | |
| WO2023155808A1 (zh) | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 | |
| US20200277268A1 (en) | Pentafluorophenyl sulfonamide compounds, compositions and uses thereof | |
| US10870662B2 (en) | Alpha-amino pateamine A derivatives and methods for treating chronic lymphocytic leukemia | |
| JP6993348B2 (ja) | β－アミノパテアミンＡ誘導体及び慢性リンパ球性白血病を治療する方法 | |
| TW202448519A (zh) | 多彈頭抗體偶聯藥物及其製備方法和用途 | |
| TW202517641A (zh) | 咪唑並喹啉胺類衍生物的藥物共軛物、組合物以及其方法 | |
| AU2016229324A1 (en) | Method for preparing largazole analogs and uses thereof | |
| US20240140947A1 (en) | Compound for the treatment of cancer | |
| WO2024155715A1 (en) | Inhibitors of activin receptor type 1 (acvr1) and activin receptor like type 1 (acvrl1), and methods using same | |
| EP4684807A1 (en) | Linker and use thereof in ligand drug conjugate | |
| TW202430140A (zh) | 奧里斯他汀(auristatin)連接子藥物(payload)、醫藥組合物及其用途 | |
| KR101597105B1 (ko) | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 | |
| HK40091854A (zh) | 抗体-药物偶联物及其用途 | |
| HK40091854B (zh) | 抗体-药物偶联物及其用途 | |
| EA047735B1 (ru) | Способ получения пегилированных соединений лекарственный препарат-линкер и их промежуточных соединений |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200330 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210301 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210903 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6993348 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |